Live Biotherapeutic Product (LBP) Market to reach over USD 2.60 billion by the year 2030- Exclusive Report by InsightAce Analytic

The global Live Biotherapeutic Product (LBP) Market is estimated to reach over USD 2.60 billion by 2030, exhibiting a CAGR of 25.2% during the forecast period.

Get Sample copy: https://www.insightaceanalytic.com/request-sample/1300

Rapid innovations in studying the interaction between the microbiota and its host have discovered evidence of the therapeutic potential of particular microbes for preventing or treating disease. Along with this research has emerged the introduction of live biotherapeutic products (LBPs) that utilise live bacteria and fungi for therapeutic purposes. Live biotherapeutic products (LBPs), an emerging type of therapy based on living bacteria, have promise for treating many complex illnesses. Several topical LBPs for the skin have entered clinical trials and are rapidly showing positive early trial results. Due to the vital significance of the human microbiome as a determinant of human health and disease, the application of Live Biotherapeutic Products (LBP) is expanding rapidly.
Rising R&D investments have largely influenced market growth. The market is further driven by a rising pipeline of microbiome-targeting treatments, growing technological advancements, innovation in creating new medications and clinical trial activities to treat illnesses.

Rising government financing and an expanded R&D budget for drug development are expected to boost market growth over the forecast period. Recently, in March 2022, Microbiotica secured a £50 million ($67 million) Series B financing transaction, the most significant microbiome-related financing in Europe to date. Microbiotica is expected to use the funds to advance its two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310, into Phase 1b clinical investigations. MB097 is a fully defined LBT composed of a collection of bacteria at the basis of Microbiotica's clinical microbiome signature that is predictive of patient response to Immune Checkpoint Inhibitor treatment.

North America dominated the market and accounted for a significant revenue share in 2021. The region is witnessing a substantial rise in the need for new, innovative treatments due to the enormous burden of bacterial infectious disease. The established healthcare sector, the existence of multinational pharmaceutical and biotech companies as well as increased investment in R&D activities in the region are additional factors promoting the expansion of this region.

List of Prominent Players in the Live Biotherapeutic Product (LBP) Market:
4D pharma plc
Seres Therapeutics, Inc.
Microbiotica
Enterome
Destiny Pharma plc
Taisho Pharmaceutical Holdings
AOBiome Therapeutics, Inc.
Finch Therapeutics Group, Inc
Ferring Pharmaceuticals
Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
MaaT Pharma
Vedanta Biosciences Inc.
OxThera AB
Pendulum Therapeutics
Caelus Health
Quorum Innovations
Sanofi S.A
DermBiont, Inc.
EnteroBiotix Ltd
YSOPIA Bioscience
Winclove Probiotics
TargEDys
Evelo Biosciences, Inc.
BiomX
Biomica Ltd.
Scioto Biosciences, Inc.
Lactobio A/S
Takeda Pharmaceutical Co. Ltd.
Second Genome Therapeutics
Johnson and Johnson Inc.
Kaleido Biosciences Inc.
OptiBiotix Health Plc
PureTech Health Plc
Immuron Limited
Naked Biome
Synthetic Biologics
ExeGi Pharma
Nexbiome
Mybiotics Pharma LTD

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1300

Recent Developments:
• In Sept 2022, TargEDys and Inoliva have entered into an exclusive marketing and distribution agreement to introduce Satylia, a food supplement containing the next-generation probiotic Hafnia alvei HA4597, to the Turkish market. Satylia, also known as EnteroSatys in other markets, is a probiotic with a well-defined molecular mechanism of action.
• In Aug 2022, 4D pharma plc announced the release of pre-clinical study on their LBP MRx0006 for the treatment of autism spectrum disorder (ASD). This publication demonstrates the sustained productivity of 4D pharma's MicroRx platform and further establishes 4D pharma as a leader in broadening the application of live biotherapeutics to disorders of the gut-brain axis.
• In Jan 2022, Takeda Pharmaceutical Firm Limited stated that it has exercised its option to purchase Adaptate Biotherapeutics ("Adaptate"). Takeda will acquire Adaptate's antibody-based T cell engager platform, which includes pre-clinical candidate and discovery pipeline programmes.

Segmentation of Live Biotherapeutic Product (LBP) Market-
By Type Of Product
• Probiotic Drugs
• Other Drugs
By Type of Molecule
• Biologics
• Small Molecules
By Target Disease Indication
• Recurrent C. difficile Infection
• Graft Versus Host Disease
• Primary Hyperoxaluria
• Necrotizing Enterocolitis
• Others
By Therapeutic Area
• Digestive and Gastrointestinal Disorders
• Infectious Diseases
• Rare Disorders
• Others
By Route Of Administration
• Oral Therapeutics
• Rectal Therapeutics

By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Enquiry Before Buying: https://www.insightaceanalytic.com/report/global-live-biotherapeutic-product-lbp-market/1300

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.